# LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

> **NCT06865885** · PHASE4 · RECRUITING · sponsor: **University of California, San Diego** · enrollment: 100 (estimated)

## Conditions studied

- Drug Interactions
- Primary Prevention
- Cardiometabolic Syndrome
- LDL-Cholersterol Lowering

## Interventions

- **DRUG:** Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

## Key facts

- **NCT ID:** NCT06865885
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-03
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06865885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06865885, "LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06865885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*